Blood test could slash unnecessary antibiotics in preterm infants

NCT ID NCT06100614

Recruiting now Disease control Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated Apr 30, 2026 · Updated 28 times

Summary

This study tests whether adding a blood test (presepsin) to standard care can safely reduce unnecessary antibiotics in premature babies born before 32 weeks. Many of these infants receive antibiotics right after birth due to infection risk, but only 1 in 70 actually has an infection. The trial will enroll 900 babies across multiple hospitals to see if the test cuts antibiotic use by at least 30% without missing real infections.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EARLY-ONSET NEONATAL SEPSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Amsterdam UMC
RECRUITING

Amsterdam, North Holland, 1105 AZ, Netherlands

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

EARLY-ONSET NEONATAL SEPSIS